Seagen positions Tukysa combo as option for breast cancer patients with brain metastases

Lei Lei Wu

News Reporter

The combination of Seagen’s Tukysa and Roche’s Kadcyla cut the risk of disease progression or death by 36% in HER2-positive breast cancer patients with brain …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Seagen positions Tukysa combo as option for breast cancer patients with brain metastases

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

FDA inspectors discover trucks carrying torn-up records leaving Indian generics factory

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

Lasker Award goes to three scientists who pioneered research behind GLP-1 drugs

Roche outlines commercial manufacturing strategy for GLP-1/GIP assets

Exclusive: Flagship-backed Valo Health loses interim CEO ahead of key Phase 2 readout

Breaking down silos with a new quantitative approach to drug development

Seagen po­si­tions Tukysa com­bo as op­tion for breast can­cer pa­tients with brain metas­tases

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Seagen positions Tukysa combo as option for breast cancer patients with brain metastases